ProCE Banner Activity

MK-8591A-052: Phase III Trial of Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV

Conference Coverage
Slideset

Results from the phase III MK-8591A-052 trial demonstrate that switching to DOR/ISL is noninferior to continuing BIC/FTC/TAF in people living with virologically suppressed HIV, with comparable changes in total lymphocyte and CD4+ cell counts.

Released: March 12, 2025

Expiration: September 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare